ReviewGastroenterology research2018
Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review.
Review in Gastroenterology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 91 citations in OpenAlex.
- Article
- Beyond the Gut: Extra-Enteric Digestive Manifestations of Inflammatory Bowel Disease-A Personalized Medicine Perspective and Comprehensive Review.Journal of personalized medicine · 2026Review
- Bidirectional interplay between gut and liver in inflammatory bowel disease and hepatobiliary conditions.Clinical and experimental medicine · 2026Review
- Klebsiella pneumoniae-induced liver abscess in a patient with ulcerative colitis: a case report and review of the literature.Journal of medical case reports · 2026Review
- Article
- Systemic Consequences of Inflammatory Bowel Disease Beyond Immune-Mediated Manifestations.Journal of clinical medicine · 2025Review
- Liver Involvement in Celiac Disease and Immune-Mediated Diseases of the Small Bowel.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Investigation of liver diseases using liver Doppler ultrasound in patients with inflammatory bowel diseases.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Article
- Association of Serum Malondialdehyde Levels with Lipid Profile and Liver Function in Patients with Inflammatory Bowel Disease.Antioxidants (Basel, Switzerland) · 2024Article
- Discerning Endoscopic Severity of Inflammatory Bowel Disease by Scoping the Peripheral Blood Transcriptome.Gastro hep advances · 2024Article
- Non-alcoholic fatty liver disease (NAFLD) and obesity in inflammatory bowel disease (IBD) patients in Gorgan.Caspian journal of internal medicine · 2024Article
- The microbiome landscape in pediatric Crohn's disease and therapeutic implications.Gut microbes · 2023Review
- TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases.Signal transduction and targeted therapy · 2023Review
- CrebH protects against liver injury associated with colonic inflammation via modulation of exosomal miRNA.Cell & bioscience · 2023Article
- Review
- Hepatobiliary manifestations in patients with ulcerative colitis: a retrospective analysis.Frontiers in medicine · 2023Article
- A Crohn's Disease Patient Found to HaveCase reports in gastrointestinal medicine · 2023Article
- Identification and clinical significance of nodular regenerative hyperplasia in primary sclerosing cholangitis.JGH open : an open access journal of gastroenterology and hepatology · 2022Article
- Hemp-Derived Nanovesicles Protect Leaky Gut and Liver Injury in Dextran Sodium Sulfate-Induced Colitis.International journal of molecular sciences · 2022Article
- Deficiency in glutathione synthesis and reduction contributes to the pathogenesis of colitis-related liver injury.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver and biliary track diseases are common extraintestinal manifestations of inflammatory bowel disease (IBD), reported both in Crohn's disease and ulcerative colitis, and may occur at any time during the natural course of the disease. Their etiology is mainly related to pathophysiological changes induced by IBD, and secondary, due to drugs used in IBD. Fatty liver is considered as the most frequent hepatobiliary manifestation in IBD, while primary sclerosing cholangitis (PSC) is the most correlated hepatobiliary disorder and is more prevalent in patients with ulcerative colitis. PSC can cause serious complications from the liver, biliary tree, and gallbladder and can lead to liver failure. Less frequently, IBD-associated hepatobiliary manifestations include cholelithiasis, granulomatous hepatitis, portal vein thrombosis, IgG4-related cholangiopathy, pyogenic liver abscess, hepatic amyloidosis and primary biliary cirrhosis. Most of the drugs used for IBD treatment may cause liver toxicity. Methotrexate and thiopurines carry the higher risk for hepatotoxicity, and in many cases, dose adjustment may normalize the liver biochemical tests. Reactivation of hepatitis B and C virus during immunosuppressive use, especially during use of biological agents, is a major concern, and adequate screening, vaccination and prophylactic treatment is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.